AstraZeneca works both sides of the Atlantic in forging new cancer drug deals

John Carroll While AstraZeneca’s busy business development team was fashioning a new discovery deal with Bind Therapeutics in Cambridge, MA, it was also polishing a pact in the ...

AstraZeneca and Boston biotech unite to blast cancer with a nanotech drug

Ryan McBride AstraZeneca has found another partner in an ongoing love fest with biotech startups. The drug giant ($ AZN), which is in the process of renovating its R&D wing, has ...

U.K. funds lambaste AstraZeneca CEO’s £4M ‘golden hello’

Tracy Staton Some U.K.pension funds are none too happy about AstraZeneca’s ($ AZN) special bonus for its new CEO, Pascal Soriot. They’re protesting Soriot’s “golden ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS